Among numerous listed stocks on ASX, there are a few that are always on the investor’s radar for them to make a potential move. Here’s a brief look at four such stocks as follows:
- EHR Resources Limited (ASX: EHX) is an ASX listed metals and mining company, holding 18% interest in its La Victoria Gold/Silver project, with an option to acquire additional 7% stake. The project Is operated by Eloro Resources Limited, covering 89 kilometre2.
On 24th April 2019, the company released its March 2019 quarterly report. In the quarter period, a reanalysis of the selected core was carried out from the 4,216m of drilling at Rufina. The company also conducted a mineral determination study from 18 representative rock samples. The local community engagement is continuing over the project with a focus on the San Markito area. Also, the company reported total net cash of A$2.69 million at the end of the reported period.
On 4th April 2019, the company was notified by ASX of a probable suspicious trading activity in its listed securities to which the company stated itself to be clean.
The company has a market capitalisation of A$3.8 million, and the stock had touched a 52-week high and low of A$0.98 and A$0.022 respectively. The stock did not trade today (as on 31 May 2019) and the last closing price was A$0.030 as of 29th May 2019.
- UUV Aquabotix Ltd (ASX: UUV) is a well-known underwater robotics company, manufacturing industrial-grade underwater drones. These drones are made on a commercial scale and for high-end consumers and military applications.
On 24th May 2019, the company announced its renounceable entitlements issue of shares that had been closed on 21st May 2019. A total of 77.07 million shares have been subscribed by existing shareholders and further 13.14 million shares subscribed for on behalf of ineligible overseas shareholders. The original issue was of 162.46 million shares, and a total of $541,313 had been raised
According to March 2019 quarterly performance, the company had received an award of ~US$70,000 in support of a United States Navy development project. In April 2019, another US$30,500 contract was awarded or the purchase of SwarmDiverTM system. At the end of the quarter period, the company had net cash of A$215,470.
Daily chart of UUV Aquabotix (Source: Thomson Reuters)
The company has a market capitalisation of A$2.02 million, and the stock had touched a 52-week high and low of A$0.074 and A$0.006 respectively. The stock decreased by 12.5% and closed at A$0.007 as of 31st May 2019. The I year return of the stock is negative 88.1%.
- Integrated Payment Technologies Limited (ASX: IP1) is a financial technology company, processing superannuation contributions on behalf of more than 43,000 Australian employers. It also provides clearing house services to some of the employers.
On 22nd May 2019, the company announced the issue of 77,349,538 new ordinary shares at A$0.01 per share to the retail investors. It also announced the change of the exercise price of its existing 5,000,000 employee options from $0.20 to $0.19575 per option.
In the quarterly update, ended 31st March 2019, the company announced the revenue of $1.22 million with an operating loss of $363,567. The net loss for the period was posted at $9.3 million. The company also reported that its ClickSuper Single Touch Payroll (STP) had increased by 100% from March to April 2019.
The company has a market capitalisation of A$5.87 million, and the stock had touched a 52-week high and low of A$0.033 and A$0.011 respectively. The stock increased by 5.2% and closed at A$0.020 as of 31st May 2019.
On 8th February 2019, the company had provided its corporate update and strategic review.
- Antisense Therapeutics Limited (ASX: ANP) is a healthcare company based in Australia. The company aims to create and deliver antisense pharmaceuticals for large untapped markets. Phase II efficacy and safety trial of ATL1102 (injection) has been successfully completed by the company, aiming to reduce the number of brain lesions.
On 26th April 2019, the company announced that it is approaching trading blackout period related to the data from ATL1102 clinical trial. Ahead of the period, the board had approved to issue up to 45 million via Loan Shares and/or options at a price of not less than $0.08 per share.
On 24th May 2019, the company announced the full enrolment of phase II clinical trial of ATL1102.
According to the March 2019 quarterly result, the company used A$778,000 for operating activities, A$1.54 had been received from financing activities. No activity was conducted on the financing side. At the end of the quarter, the company reported net cash of A$3.67 million.
The company has a market capitalisation of A$21.01 million, and the stock had touched a 52-week high and low of A$0.094 and A$0.017 respectively. The stock increased by 4% and closed at A$0.052 as of 31st May 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.